Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study of Autologous MSC-NTF Cells in Patients With ALS

NCT02017912 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

48

Enrollment

INDUSTRY

Sponsor class

Conditions

Amyotrophic Lateral Sclerosis (ALS)

Interventions

BIOLOGICAL: Nurown MSC-NTF cells
BIOLOGICAL: Placebo

Sponsor

Brainstorm-Cell Therapeutics